Inhibitory leukocyte immunoglobulin-like receptors: Immune checkpoint proteins and tumor sustaining factors

Cell Cycle

Volumn 15, Issue 1, 2016, Pages 25-40

  Kang, Xunlei ^a   Kim, Jaehyup ^a   Deng, Mi ^a   John, Samuel ^a   Chen, Heyu ^a   Wu, Guojin ^a   Phan, Hiep ^a   Zhang, Cheng Cheng ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Cancer; CD85; HLA; ILT; Immunoglobulin like transcript; Immunoreceptor tyrosine based activation motif; Immunoreceptor tyrosine based inhibitory motifs; ITAM; ITIM; Leukemia; Leukocyte immunoglobulinlike receptor; Leukocyte immunoglobulinlike receptor subfamily B; LILRB; LIR; MHC; Phosphatase; SHIP; SHP 1; SHP 2; Signal transduction

Indexed keywords

LEUKOCYTE IMMUNOGLOBULIN LIKE RECEPTOR 1; LEUKOCYTE IMMUNOGLOBULIN LIKE RECEPTOR 2; LEUKOCYTE IMMUNOGLOBULIN LIKE RECEPTOR 3; LEUKOCYTE IMMUNOGLOBULIN LIKE RECEPTOR 4; LEUKOCYTE IMMUNOGLOBULIN LIKE RECEPTOR 5; LIGAND; LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG; IMMUNOGLOBULIN RECEPTOR; LEUKOCYTE ANTIGEN; LILRB1 PROTEIN, HUMAN; PROTEIN TYROSINE PHOSPHATASE SHP 1; PTPN6 PROTEIN, HUMAN;

B LYMPHOCYTE; CANCER CELL; CARCINOGENESIS; DENDRITIC CELL; HEMATOPOIESIS; HEMATOPOIETIC CELL; HUMAN; IMMUNOCOMPETENT CELL; IMMUNORECEPTOR TYROSINE BASED ACTIVATION MOTIF; LEUKEMIA CELL; MACROPHAGE; MONOCYTE; NATURAL KILLER CELL; NERVE CELL; OSTEOCLAST; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TUMOR CELL; ANIMAL; GENE; IMMUNOLOGY; METABOLISM; NEOPLASM; PHYSIOLOGY;

ANIMALS; ANTIGENS, CD; GENES, CDC; HUMANS; NEOPLASMS; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 6; RECEPTORS, IMMUNOLOGIC; SIGNAL TRANSDUCTION;

EID: 84964262315     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.1080/15384101.2015.1121324     Document Type: Review

References (189)

1. Daeron M, Latour S, Malbec O, Espinosa E, Pina P, Pasmans S, Fridman WH. The same tyrosine-based inhibition motif, in the intracytoplasmic domain of Fc gamma RIIB, regulates negatively BCR-, TCR-, and FcR-dependent cell activation. Immunity 1995; 3:635-46; http://dx.doi.org/10.1016/1074-7613(95)90134-5
2. Staub E, Rosenthal A, Hinzmann B. Systematic identification of immunoreceptor tyrosine-based inhibitory motifs in the human proteome. Cell Signal 2004; 16:435-56;http://dx.doi.org/10.1016/j.cellsig.2003.08.013
3. Takai T, Nakamura A, Endo S. Role of PIR-B in autoimmune glomerulonephritis. J Biomed Biotechnol 2011; 2011:275302; http://dx.doi.org/10.1155/2011/275302
4. Daeron M, Jaeger S, Du Pasquier L, Vivier E. Immunoreceptor tyrosine-based inhibition motifs: a quest in the past and future. Immunol Rev 2008; 224:11-43; http://dx.doi.org/10.1111/j.1600-065X.2008.00666.x
5. Katz HR. Inhibition of inflammatory responses by leukocyte Ig-like receptors. Adv Immunol 2006; 91:251-72; http://dx.doi.org/10.1016/S0065-2776(06)91007-4
6. Bruhns P, Vely F, Malbec O, Fridman WH, Vivier E, Daeron M. Molecular basis of the recruitment of the SH2 domain-containing inositol 5-phosphatases SHIP1 and SHIP2 by fcgamma RIIB. J Biol Chem 2000; 275:37357-64; http://dx.doi.org/10.1074/jbc.M003518200
7. Huang ZY, Hunter S, Kim MK, Indik ZK, Schreiber AD. The effect of phosphatases SHP-1 and SHIP-1 on signaling by the ITIM-and ITAM-containing Fcgamma receptors FcgammaRIIB and FcgammaRIIA. J Leukocyte Biol 2003; 73:823-9 http://dx.doi.org/10.1189/jlb.0902454
8. Binstadt BA, Brumbaugh KM, Dick CJ, Scharenberg AM, Williams BL, Colonna M, Lanier LL, Kinet JP, Abraham RT, Leibson PJ. Sequential involvement of Lck and SHP-1 with MHC-recognizing receptors on NK cells inhibits FcR-initiated tyrosine kinase activation. Immunity 1996; 5:629-38 http://dx.doi.org/10.1016/S1074-7613(00)80276-9
9. Daigle I, Yousefi S, Colonna M, Green DR, Simon HU. Death receptors bind SHP-1 and block cytokine-induced anti-apoptotic signaling in neutrophils. Nat Med 2002; 8:61-7 http://dx.doi.org/10.1038/nm0102-61
10. Stebbins CC, Watzl C, Billadeau DD, Leibson PJ, Burshtyn DN, Long EO. Vav1 dephosphorylation by the tyrosine phosphatase SHP-1 as a mechanism for inhibition of cellular cytotoxicity. Mol Cell Biol 2003; 23:6291-9 http://dx.doi.org/10.1128/MCB.23.17.6291-6299.2003
11. Ivashkiv LB. Cross-regulation of signaling by ITAM-associated receptors. Nat Immunol 2009; 10:340-7 http://dx.doi.org/10.1038/ni.1706
12. Borges L, Hsu ML, Fanger N, Kubin M, Cosman D. A family of human lymphoid and myeloid Ig-like receptors, some of which bind to MHC class I molecules. J Immunol (Baltimore, Md : 1950) 1997; 159:5192-6
13. Colonna M, Navarro F, Bellon T, Llano M, Garcia P, Samaridis J, Angman L, Cella M, Lopez-Botet M. A common inhibitory receptor for major histocompatibility complex class I molecules on human lymphoid and myelomonocytic cells. J Exp Med 1997; 186:1809-18 http://dx.doi.org/10.1084/jem.186.11.1809
14. Cella M, Dohring C, Samaridis J, Dessing M, Brockhaus M, Lanzavecchia A, Colonna M. A novel inhibitory receptor (ILT3) expressed on monocytes, macrophages, and dendritic cells involved in antigen processing. J Exp Med 1997; 185:1743-51 http://dx.doi.org/10.1084/jem.185.10.1743
15. Samaridis J, Colonna M. Cloning of novel immunoglobulin superfamily receptors expressed on human myeloid and lymphoid cells: structural evidence for new stimulatory and inhibitory pathways. Eur J Immunol 1997; 27:660-5 http://dx.doi.org/10.1002/eji.1830270313
16. Martin AM, Kulski JK, Witt C, Pontarotti P, Christiansen FT. Leukocyte Ig-like receptor complex (LRC) in mice and men. Trend Immunol 2002; 23:81-8 http://dx.doi.org/10.1016/S1471-4906(01)02155-X
17. Wende H, Colonna M, Ziegler A, Volz A. Organization of the leukocyte receptor cluster (LRC) on human chromosome 19q13.4. Mammalian Gen 1999; 10:154-60 http://dx.doi.org/10.1007/s003359900961
18. Kubagawa H, Burrows PD, Cooper MD. A novel pair of immunoglobulin-like receptors expressed by B cells and myeloid cells. Proc Natl Acad Sci U S A 1997; 94:5261-6 http://dx.doi.org/10.1073/pnas.94.10.5261
19. Katz HR, Vivier E, Castells MC, McCormick MJ, Chambers JM, Austen KF. Mouse mast cell gp49B1 contains two immunoreceptor tyrosine-based inhibition motifs and suppresses mast cell activation when coligated with the high-affinity Fc receptor for IgE. Proc Natl Acad Sci U S A 1996; 93:10809-14 http://dx.doi.org/10.1073/pnas.93.20.10809
20. Mori Y, Tsuji S, Inui M, Sakamoto Y, Endo S, Ito Y, Fujimura S, Koga T, Nakamura A, Takayanagi H, et al. Inhibitory immunoglobulin-like receptors LILRB and PIR-B negatively regulate osteoclast development. J Immunol 2008; 181:4742-51 http://dx.doi.org/10.4049/jimmunol.181.7.4742
21. Zheng J, Umikawa M, Cui C, Li J, Chen X, Zhang C, Hyunh H, Kang X, Silvany R, Wan X, et al. Inhibitory receptors bind ANGPTLs and support blood stem cells and leukaemia development. Nature 2012; 485:656-60 http://dx.doi.org/10.1038/nature11095
22. Deng M, Lu Z, Zheng J, Wan X, Chen X, Hirayasu K, Sun H, Lam Y, Chen L, Wang Q, et al. A motif in LILRB2 critical for Angptl2 binding and activation. Blood 2014; 124:924-35 http://dx.doi.org/10.1182/blood-2014-01-549162
23. Atwal JK, Pinkston-Gosse J, Syken J, Stawicki S, Wu Y, Shatz C, Tessier-Lavigne M. PirB is a functional receptor for myelin inhibitors of axonal regeneration. Science 2008; 322:967-70 http://dx.doi.org/10.1126/science.1161151
24. Kim T, Vidal GS, Djurisic M, William CM, Birnbaum ME, Garcia KC, Hyman BT, Shatz CJ. Human LilrB2 is a beta-amyloid receptor and its murine homolog PirB regulates synaptic plasticity in an Alzheimer’s model. Science 2013; 341:1399-404 http://dx.doi.org/10.1126/science.1242077
25. Sharma P, Allison JP. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell 2015; 161:205-14 http://dx.doi.org/10.1016/j.cell.2015.03.030
26. Carosella ED, Rouas-Freiss N, Roux DT, Moreau P, LeMaoult J. HLA-G: An Immune Checkpoint Molecule. Adv Immunol 2015; 127:33-144 http://dx.doi.org/10.1016/bs.ai.2015.04.001
27. Olde Nordkamp MJ, van Eijk M, Urbanus RT, Bont L, Haagsman HP, Meyaard L. Leukocyte-associated Ig-like receptor-1 is a novel inhibitory receptor for surfactant protein D. J Leukoc Biol 2014; 96:105-11 http://dx.doi.org/10.1189/jlb.3AB0213-092RR
28. Meyaard L, Adema GJ, Chang C, Woollatt E, Sutherland GR, Lanier LL, Phillips JH. LAIR-1, a novel inhibitory receptor expressed on human mononuclear leukocytes. Immunity 1997; 7:283-90 http://dx.doi.org/10.1016/S1074-7613(00)80530-0
29. Poggi A, Pella N, Morelli L, Spada F, Revello V, Sivori S, Augugliaro R, Moretta L, Moretta A. p40, a novel surface molecule involved in the regulation of the non-major histocompatibility complex-restricted cytolytic activity in humans. Eur J Immunol 1995; 25:369-76 http://dx.doi.org/10.1002/eji.1830250210
30. Lebbink RJ, de Ruiter T, Adelmeijer J, Brenkman AB, van Helvoort JM, Koch M, Farndale RW, Lisman T, Sonnenberg A, Lenting PJ, et al. Collagens are functional, high affinity ligands for the inhibitory immune receptor LAIR-1. J Exp Med 2006; 203:1419-25 http://dx.doi.org/10.1084/jem.20052554
31. Kang X, Lu Z, Cui C, Deng M, Fan Y, Dong B, Han X, Xie F, Tyner JW, Coligan JE, et al. The ITIM-containing receptor LAIR1 is essential for acute myeloid leukaemia development. Nat Cell Biol 2015; 17:665-77 http://dx.doi.org/10.1038/ncb3158
32. Liu X, Yu X, Xie J, Zhan M, Yu Z, Xie L, Zeng H, Zhang F, Chen G, Yi X, et al. ANGPTL2/LILRB2 signaling promotes the propagation of lung cancer cells. Oncotarget 2015; 6:21004-15
33. Wang L, Geng T, Guo X, Liu J, Zhang P, Yang D, Li J, Yu S, Sun Y. Co-expression of immunoglobulin-like transcript 4 and angiopoietin-like proteins in human non-small cell lung cancer. Mol Med Rep 2015; 11:2789-96
34. Zhang P, Yu S, Li H, Liu C, Li J, Lin W, Gao A, Wang L, Gao W, Sun Y. ILT4 drives B7-H3 expression via PI3K/AKT/mTOR signalling and ILT4/B7-H3 co-expression correlates with poor prognosis in non-small cell lung cancer. FEBS Lett 2015; 589:2248-56
35. Naji A, Menier C, Maki G, Carosella ED, Rouas-Freiss N. Neoplastic B-cell growth is impaired by HLA-G/ILT2 interaction. Leukemia 2012; 26:1889-92 http://dx.doi.org/10.1038/leu.2012.62
36. Harly C, Peyrat MA, Netzer S, Dechanet-Merville J, Bonneville M, Scotet E. Up-regulation of cytolytic functions of human Vdelta2-gamma T lymphocytes through engagement of ILT2 expressed by tumor target cells. Blood 2011; 117:2864-73 http://dx.doi.org/10.1182/blood-2010-09-309781
37. Urosevic M, Kamarashev J, Burg G, Dummer R. Primary cutaneous CD8C and CD56C T-cell lymphomas express HLA-G and killer-cell inhibitory ligand, ILT2. Blood 2004; 103:1796-8 http://dx.doi.org/10.1182/blood-2003-10-3372
38. Zhang Y, Lu N, Xue Y, Zhang M, Li Y, Si Y, Bian X, Jia Y, Wang Y. Expression of immunoglobulin-like transcript (ILT)2 and ILT3 in human gastric cancer and its clinical significance. Mol Med Rep 2012; 5:910-6
39. Heidenreich S, Zu Eulenburg C, Hildebrandt Y, Stubig T, Sierich H, Badbaran A, Eiermann TH, Binder TM, Kroger N. Impact of the NK cell receptor LIR-1 (ILT-2/CD85j/LILRB1) on cytotoxicity against multiple myeloma. Clin Dev Immunol 2012; 2012:652130 http://dx.doi.org/10.1155/2012/652130
40. Colovai AI, Tsao L, Wang S, Lin H, Wang C, Seki T, Fisher JG, Menes M, Bhagat G, Alobeid B, et al. Expression of inhibitory receptor ILT3 on neoplastic B cells is associated with lymphoid tissue involvement in chronic lymphocytic leukemia. Cytometry B Clin Cytom 2007; 72:354-62 http://dx.doi.org/10.1002/cyto.b.20164
41. Liu J, Wang L, Gao W, Li L, Cui X, Yang H, Lin W, Dang Q, Zhang N, Sun Y. Inhibitory receptor immunoglobulin-like transcript 4 was highly expressed in primary ductal and lobular breast cancer and significantly correlated with IL-10. Diagn Pathol 2014; 9:85 http://dx.doi.org/10.1186/1746-1596-9-85
42. Sun Y, Liu J, Gao P, Wang Y, Liu C. Expression of Ig-like transcript 4 inhibitory receptor in human non-small cell lung cancer. Chest 2008; 134:783-8 http://dx.doi.org/10.1378/chest.07-1100
43. Pfistershammer K, Lawitschka A, Klauser C, Leitner J, Weigl R, Heemskerk MH, Pickl WF, Majdic O, Bohmig GA, Fischer GF, et al. Allogeneic disparities in immunoglobulin-like transcript 5 induce potent antibody responses in hematopoietic stem cell transplant recipients. Blood 2009; 114:2323-32 http://dx.doi.org/10.1182/blood-2008-10-183814
44. Suciu-Foca N, Feirt N, Zhang QY, Vlad G, Liu Z, Lin H, Chang CC, Ho EK, Colovai AI, Kaufman H, et al. Soluble Ig-like transcript 3 inhibits tumor allograft rejection in humanized SCID mice and T cell responses in cancer patients. J Immunol 2007; 178:7432-41 http://dx.doi.org/10.4049/jimmunol.178.11.7432
45. Cortesini R. Pancreas cancer and the role of soluble immunoglobulin-like transcript 3 (ILT3). JOP 2007; 8:697-703
46. Chen Z, Shojaee S, Buchner M, Geng H, Lee JW, Klemm L, Titz B, Graeber TG, Park E, Tan YX, et al. Signalling thresholds and negative B-cell selection in acute lymphoblastic leukaemia. Nature 2015; 521:357-61 http://dx.doi.org/10.1038/nature14231
47. Ma G, Pan PY, Eisenstein S, Divino CM, Lowell CA, Takai T, Chen SH. Paired immunoglobin-like receptor-B regulates the suppressive function and fate of myeloid-derived suppressor cells. Immunity 2011; 34:385-95 http://dx.doi.org/10.1016/j.immuni.2011.02.004
48. Hirayasu K, Arase H. Functional and genetic diversity of leukocyte immunoglobulin-like receptor and implication for disease associations. J Hum Gen 2015
49. Barrow AD, Trowsdale J. The extended human leukocyte receptor complex: diverse ways of modulating immune responses. Immunol Rev 2008; 224:98-123 http://dx.doi.org/10.1111/j.1600-065X.2008.00653.x
50. Trowsdale J, Jones DC, Barrow AD, Traherne JA. Surveillance of cell and tissue perturbation by receptors in the LRC. Immunol Rev 2015; 267:117-36 http://dx.doi.org/10.1111/imr.12314
51. Willcox BE, Thomas LM, Bjorkman PJ. Crystal structure of HLA-A2 bound to LIR-1, a host and viral major histocompatibility complex receptor. Nat Immunol 2003; 4:913-9 http://dx.doi.org/10.1038/ni961
52. Colonna M, Samaridis J, Cella M, Angman L, Allen RL, O’Callaghan CA, Dunbar R, Ogg GS, Cerundolo V, Rolink A. Human myelomonocytic cells express an inhibitory receptor for classical and nonclassical MHC class I molecules. J Immunol (Baltimore, Md : 1950) 1998; 160:3096-100
53. Shiroishi M, Tsumoto K, Amano K, Shirakihara Y, Colonna M, Braud VM, Allan DS, Makadzange A, Rowland-Jones S, Willcox B, et al. Human inhibitory receptors Ig-like transcript 2 (ILT2) and ILT4 compete with CD8 for MHC class I binding and bind preferentially to HLA-G. Proc Natl Acad Sci U S A 2003; 100:8856-61 http://dx.doi.org/10.1073/pnas.1431057100
54. Zhang Z, Hatano H, Shaw J, Olde Nordkamp M, Jiang G, Li D, Kollnberger S. The Leukocyte Immunoglobulin-Like Receptor Family Member LILRB5 Binds to HLA-Class I Heavy Chains. PLoS One 2015; 10:e0129063 http://dx.doi.org/10.1371/journal.pone.0129063
55. Fridman WH. Fc receptors and immunoglobulin binding factors. FASEB J 1991; 5:2684-90
56. Li D, Wang L, Yu L, Freundt EC, Jin B, Screaton GR, Xu XN. Ig-like transcript 4 inhibits lipid antigen presentation through direct CD1d interaction. J Immunol 2009; 182:1033-40 http://dx.doi.org/10.4049/jimmunol.182.2.1033
57. Arnold V, Cummings JS, Moreno-Nieves UY, Didier C, Gilbert A, Barre-Sinoussi F, Scott-Algara D. S100A9 protein is a novel ligand for the CD85j receptor and its interaction is implicated in the control of HIV-1 replication by NK cells. Retrovirology 2013; 10:122 http://dx.doi.org/10.1186/1742-4690-10-122
58. Torii I, Oka S, Hotomi M, Benjamin WH, Jr., Takai T, Kearney JF, Briles DE, Kubagawa H. PIR-B-deficient mice are susceptible to Salmonella infection. J Immunol 2008; 181:4229-39; http://dx.doi.org/10.4049/jimmunol.181.6.4229
59. Takai T. Paired immunoglobulin-like receptors and their MHC class I recognition. Immunology 2005; 115:433-40 http://dx.doi.org/10.1111/j.1365-2567.2005.02177.x
60. Castells MC, Klickstein LB, Hassani K, Cumplido JA, Lacouture ME, Austen KF, Katz HR. gp49B1-alpha(v)beta3 interaction inhibits antigen-induced mast cell activation. Nat Immunol 2001; 2:436-42
61. Dobrowolska H, Gill KZ, Serban G, Ivan E, Li Q, Qiao P, Suciu-Foca N, Savage D, Alobeid B, Bhagat G, et al. Expression of immune inhibitory receptor ILT3 in acute myeloid leukemia with monocytic differentiation. Cytometry B Clin Cytom 2013; 84:21-9 http://dx.doi.org/10.1002/cyto.b.21050
62. Blery M, Kubagawa H, Chen CC, Vely F, Cooper MD, Vivier E. The paired Ig-like receptor PIR-B is an inhibitory receptor that recruits the protein-tyrosine phosphatase SHP-1. Proc Natl Acad Sci U S A 1998; 95:2446-51 http://dx.doi.org/10.1073/pnas.95.5.2446
63. Rojo S, Stebbins CC, Peterson ME, Dombrowicz D, Wagtmann N, Long EO. Natural killer cells and mast cells from gp49B null mutant mice are functional. Mol Cell Biol 2000; 20:7178-82 http://dx.doi.org/10.1128/MCB.20.19.7178-7182.2000
64. Mitsuhashi Y, Nakamura A, Endo S, Takeda K, Yabe-Wada T, Nukiwa T, Takai T. Regulation of plasmacytoid dendritic cell responses by PIR-B. Blood 2012; 120:3256-9 http://dx.doi.org/10.1182/blood-2012-03-419093
65. Tang X, Tian L, Esteso G, Choi SC, Barrow AD, Colonna M, Borrego F, Coligan JE. Leukocyte-associated Ig-like receptor-1-deficient mice have an altered immune cell phenotype. J Immunol 2012; 188: 548-58 http://dx.doi.org/10.4049/jimmunol.1102044
66. Hunt JS, Petroff MG, Morales P, Sedlmayr P, Geraghty DE, Ober C. HLA-G in reproduction: studies on the maternal-fetal interface. Human immunology 2000; 61:1113-7 http://dx.doi.org/10.1016/S0198-8859(00)00195-6
67. Tedla N, Lee CW, Borges L, Geczy CL, Arm JP. Differential expression of leukocyte immunoglobulin-like receptors on cord-bloodderived human mast cell progenitors and mature mast cells. J Leukoc Biol 2008; 83:334-43 http://dx.doi.org/10.1189/jlb.0507314
68. Davidson CL, Li NL, Burshtyn DN. LILRB1 polymorphism and surface phenotypes of natural killer cells. Hum Immunol 2010; 71: 942-9 http://dx.doi.org/10.1016/j.humimm.2010.06.015
69. Lamar DL, Weyand CM, Goronzy JJ. Promoter choice and translational repression determine cell type-specific cell surface density of the inhibitory receptor CD85j expressed on different hematopoietic lineages. Blood 2010; 115:3278-86 http://dx.doi.org/10.1182/blood-2009-09-243493
70. Lepin EJ, Bastin JM, Allan DS, Roncador G, Braud VM, Mason DY, van der Merwe PA, McMichael AJ, Bell JI, Powis SH, et al. Functional characterization of HLA-F and binding of HLA-F tetramers to ILT2 and ILT4 receptors. Eur J Immunol 2000; 30:3552-61 http://dx.doi.org/10.1002/1521-4141(200012) 30:12%3c3552::AID-IMMU3552%3e3.0.CO;2-L
71. Allan DS, Lepin EJ, Braud VM, O’Callaghan CA, McMichael AJ. Tetrameric complexes of HLA-E, HLA-F, and HLA-G. J Immun Methods 2002; 268:43-50 http://dx.doi.org/10.1016/S0022-1759(02)00199-0
72. Shiroishi M, Kuroki K, Ose T, Rasubala L, Shiratori I, Arase H, Tsumoto K, Kumagai I, Kohda D, Maenaka K. Efficient leukocyte Ig-like receptor signaling and crystal structure of disulfide-linked HLA-G dimer. J Biol Chem 2006; 281:10439-47 http://dx.doi.org/10.1074/jbc.M512305200
73. Chapman TL, Heikeman AP, Bjorkman PJ. The inhibitory receptor LIR-1 uses a common binding interaction to recognize class I MHC molecules and the viral homolog UL18. Immunity 1999; 11:603-13 http://dx.doi.org/10.1016/S1074-7613(00)80135-1
74. Chapman TL, Heikema AP, West AP, Jr., Bjorkman PJ. Crystal structure and ligand binding properties of the D1D2 region of the inhibitory receptor LIR-1 (ILT2). Immunity 2000; 13:727-36 http://dx.doi.org/10.1016/S1074-7613(00)00071-6
75. Allen RL, Raine T, Haude A, Trowsdale J, Wilson MJ. Leukocyte receptor complex-encoded immunomodulatory receptors show differing specificity for alternative HLA-B27 structures. J Immunol 2001; 167:5543-7; http://dx.doi.org/10.4049/jimmunol.167.10.5543
76. Vitale M, Castriconi R, Parolini S, Pende D, Hsu ML, Moretta L, Cosman D, Moretta A. The leukocyte Ig-like receptor (LIR)-1 for the cytomegalovirus UL18 protein displays a broad specificity for different HLA class I alleles: analysis of LIR-1 C NK cell clones. Inter Immunol 1999; 11:29-35 http://dx.doi.org/10.1093/intimm/11.1.29
77. Navarro F, Llano M, Bellon T, Colonna M, Geraghty DE, Lopez-Botet M. The ILT2(LIR1) and CD94/NKG2A NK cell receptors respectively recognize HLA-G1 and HLA-E molecules co-expressed on target cells. Eur J Immunol 1999; 29:277-83 http://dx.doi.org/10.1002/(SICI)1521-4141(199901)29:01%3c277::AID-IMMU277%3e3.0.CO;2-4
78. Morel E, Bellon T. HLA class I molecules regulate IFN-g production induced in NK cells by target cells, viral products, or immature dendritic cells through the inhibitory receptor ILT2/CD85j. J Immunol 2008; 181:2368-81 http://dx.doi.org/10.4049/jimmunol.181.4.2368
79. LeMaoult J, Zafaranloo K, Le Danff C, Carosella ED. HLA-G up-regulates ILT2, ILT3, ILT4, and KIR2DL4 in antigen presenting cells, NK cells, and T cells. FASEB J 2005; 19:662-4
80. Favier B, Lemaoult J, Lesport E, Carosella ED. ILT2/HLA-G interaction impairs NK-cell functions through the inhibition of the late but not the early events of the NK-cell activating synapse. FASEB J 2010; 24:689-99 http://dx.doi.org/10.1096/fj.09-135194
81. Ponte M, Cantoni C, Biassoni R, Tradori-Cappai A, Bentivoglio G, Vitale C, Bertone S, Moretta A, Moretta L, Mingari MC. Inhibitory receptors sensing HLA-G1 molecules in pregnancy: decidua-associated natural killer cells express LIR-1 and CD94/NKG2A and acquire p49, an HLA-G1-specific receptor. Proc Natl Acad Sci U S A 1999; 96:5674-9 http://dx.doi.org/10.1073/pnas.96.10.5674
82. Petroff MG, Sedlmayr P, Azzola D, Hunt JS. Decidual macrophages are potentially susceptible to inhibition by class Ia and class Ib HLA molecules. J Reproduct Immunol 2002; 56:3-17 http://dx.doi.org/10.1016/S0165-0378(02)00024-4
83. Mamessier E, Sylvain A, Thibult ML, Houvenaeghel G, Jacquemier J, Castellano R, Goncalves A, Andre P, Romagne F, Thibault G, et al. Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity. J Clin Invest 2011; 121:3609-22 http://dx.doi.org/10.1172/JCI45816
84. Roberti MP, Julia EP, Rocca YS, Amat M, Bravo AI, Loza J, Colo F, Loza CM, Fabiano V, Maino M. Overexpression of CD85j in TNBC patients inhibits Cetuximab-mediated NK-cell ADCC but can be restored with CD85j functional blockade. Eur J Immunol 2015; 45:1560-9 http://dx.doi.org/10.1002/eji.201445353
85. Kirwan SE, Burshtyn DN. Killer cell Ig-like receptor-dependent signaling by Ig-like transcript 2 (ILT2/CD85j/LILRB1/LIR-1). J Immunol 2005; 175:5006-15; http://dx.doi.org/10.4049/jimmunol.175.8.5006
86. Godal R, Bachanova V, Gleason M, McCullar V, Yun GH, Cooley S, Verneris MR, McGlave PB, Miller JS. Natural killer cell killing of acute myelogenous leukemia and acute lymphoblastic leukemia blasts by killer cell immunoglobulin-like receptor-negative natural killer cells after NKG2A and LIR-1 blockade. Biol Blood Marrow Trans 2010; 16:612-21 http://dx.doi.org/10.1016/j.bbmt.2010.01.019
87. Li C, Houser BL, Nicotra ML, Strominger JL. HLA-G homodimerinduced cytokine secretion through HLA-G receptors on human decidual macrophages and natural killer cells. Proc Natl Acad Sci U S A 2009; 106:5767-72 http://dx.doi.org/10.1073/pnas.0901173106
88. Scott-Algara D, Arnold V, Didier C, Kattan T, Pirozzi G, Barre-Sinoussi F, Pancino G. The CD85jC NK cell subset potently controls HIV-1 replication in autologous dendritic cells. PloS one 2008; 3: e1975 http://dx.doi.org/10.1371/journal. pone.0001975
89. Fanger NA, Cosman D, Peterson L, Braddy SC, Maliszewski CR, Borges L. The MHC class I binding proteins LIR-1 and LIR-2 inhibit Fc receptor-mediated signaling in monocytes. Eur J Immunol 1998; 28:3423-34 http://dx.doi.org/10.1002/(SICI) 1521-4141(199811)28:11%3c3423::AID-IMMU3423%3e3.0.CO;2-2
90. Lombardelli L, Aguerre-Girr M, Logiodice F, Kullolli O, Casart Y, Polgar B, Berrebi A, Romagnani S, Maggi E, Le Bouteiller P. HLA-G5 induces IL-4 secretion critical for successful pregnancy through differential expression of ILT2 receptor on decidual CD4C T cells and macrophages. J Immunol 2013; 191:3651-62 http://dx.doi.org/10.4049/jimmunol.1300567
91. Lefebvre S, Antoine M, Uzan S, McMaster M, Dausset J, Carosella ED, Paul P. Specific activation of the non-classical class I histocompatibility HLA-G antigen and expression of the ILT2 inhibitory receptor in human breast cancer. J Pathol 2002; 196:266-74 http://dx.doi.org/10.1002/path.1039
92. Ju XS, Hacker C, Scherer B, Redecke V, Berger T, Schuler G, Wagner H, Lipford GB, Zenke M. Immunoglobulin-like transcripts ILT2, ILT3 and ILT7 are expressed by human dendritic cells and downregulated following activation. Gene 2004; 331:159-64 http://dx.doi.org/10.1016/j.gene.2004.02.018
93. Young NT, Waller EC, Patel R, Roghanian A, Austyn JM, Trowsdale J. The inhibitory receptor LILRB1 modulates the differentiation and regulatory potential of human dendritic cells. Blood 2008; 111: 3090-6 http://dx.doi.org/10.1182/blood-2007-05-089771
94. Fedoric B, Krishnan R. Rapamycin downregulates the inhibitory receptors ILT2, ILT3, ILT4 on human dendritic cells and yet induces T cell hyporesponsiveness independent of FoxP3 induction. Immunol Lett 2008; 120:49-56 http://dx.doi.org/10.1016/j.imlet.2008.06.009
95. Tenca C, Merlo A, Merck E, Bates EE, Saverino D, Simone R, Zarcone D, Trinchieri G, Grossi CE, Ciccone E. CD85j (leukocyte Ig-like receptor-1/Ig-like transcript 2) inhibits human osteoclast-associated receptor-mediated activation of human dendritic cells. J Immunol 2005; 174:6757-63; http://dx.doi.org/10.4049/jimmunol.174.11.6757
96. Apps R, Gardner L, Sharkey AM, Holmes N, Moffett A. A homodimeric complex of HLA-G on normal trophoblast cells modulates antigen-presenting cells via LILRB1. Eur J Immunol 2007; 37: 1924-37 http://dx.doi.org/10.1002/eji.200737089
97. Monsivais-Urenda A, Gomez-Martin D, Santana-de-Anda K, Cruz-Martinez J, Alcocer-Varela J, Gonzalez-Amaro R. Defective expression and function of the ILT2/CD85j regulatory receptor in dendritic cells from patients with systemic lupus erythematosus. Hum Immunol 2013; 74:1088-96 http://dx.doi.org/10.1016/j.humimm.2013.05.006
98. Huang J, Burke PS, Cung TD, Pereyra F, Toth I, Walker BD, Borges L, Lichterfeld M, Yu XG. Leukocyte immunoglobulin-like receptors maintain unique antigen-presenting properties of circulating myeloid dendritic cells in HIV-1-infected elite controllers. J Virol 2010; 84:9463-71 http://dx.doi.org/10.1128/JVI.01009-10
99. Banham AH, Colonna M, Cella M, Micklem KJ, Pulford K, Willis AC, Mason DY. Identification of the CD85 antigen as ILT2, an inhibitory MHC class I receptor of the immunoglobulin superfamily. J Leukocyte Biol 1999; 65:841-5
100. Young NT, Uhrberg M, Phillips JH, Lanier LL, Parham P. Differential expression of leukocyte receptor complex-encoded Ig-like receptors correlates with the transition from effector to memory CTL. J Immunol 2001; 166:3933-41; http://dx.doi.org/10.4049/jimmunol.166.6.3933
101. Saverino D, Fabbi M, Ghiotto F, Merlo A, Bruno S, Zarcone D, Tenca C, Tiso M, Santoro G, Anastasi G, et al. The CD85/LIR-1/ILT2 inhibitory receptor is expressed by all human T lymphocytes and downregulates their functions. J Immunol 2000; 165:3742-55; http://dx.doi.org/10.4049/jimmunol.165.7.3742
102. Ince MN, Harnisch B, Xu Z, Lee SK, Lange C, Moretta L, Lederman M, Lieberman J. Increased expression of the natural killer cell inhibitory receptor CD85j/ILT2 on antigen-specific effector CD8 T cells and its impact on CD8 T-cell function. Immunology 2004; 112:531-42 http://dx.doi.org/10.1046/j.1365-2567.2004.01907.x
103. Saverino D, Merlo A, Bruno S, Pistoia V, Grossi CE, Ciccone E. Dual effect of CD85/leukocyte Ig-like receptor-1/Ig-like transcript 2 and CD152 (CTLA-4) on cytokine production by antigen-stimulated human T cells. J Immunol (Baltimore, Md : 1950) 2002; 168:207-15 http://dx.doi.org/10.4049/jimmunol.168.1.207
104. Merlo A, Saverino D, Tenca C, Grossi CE, Bruno S, Ciccone E. CD85/LIR-1/ILT2 and CD152 (Cytotoxic T Lymphocyte Antigen 4) Inhibitory Molecules Down-Regulate the Cytolytic Activity of Human CD4C T-Cell Clones Specific forMycobacterium tuberculosis. Infect Immun 2001; 69:6022-9 http://dx.doi.org/10.1128/IAI.69.10.6022-6029.2001
105. Dietrich J, Cella M, Colonna M. Ig-like transcript 2 (ILT2)/leukocyte Ig-like receptor 1 (LIR1) inhibits TCR signaling and actin cytoskeleton reorganization. J Immunol 2001; 166:2514-21 http://dx.doi.org/10.4049/jimmunol.166.4.2514
106. Zhang W, Liang S, Wu J, Horuzsko A. Human Inhibitory Receptor ILT2 Amplifies CD11bC Gr1C Myeloid-Derived Suppressor Cells that Promote Long-Term Survival of Allografts. Transplantation 2008; 86:1125 http://dx.doi.org/10.1097/TP.0b013e318186fccd
107. Liang S, Zhang W, Horuzsko A. Human ILT2 receptor associates with murine MHC class I molecules in vivo and impairs T cell function. Eur J Immunol 2006; 36:2457-71 http://dx.doi.org/10.1002/eji.200636031
108. Lesport E, Baudhuin J, Sousa S, LeMaoult J, Zamborlini A, Rouas-Freiss N, Carosella ED, Favier B. Inhibition of human gamma delta [corrected] T-cell antitumoral activity through HLA-G: implications for immunotherapy of cancer. Cell Mol Life Sci 2011; 68:3385-99 http://dx.doi.org/10.1007/s00018-011-0632-7
109. Saverino D, Ghiotto F, Merlo A, Bruno S, Battini L, Occhino M, Maffei M, Tenca C, Pileri S, Baldi L, et al. Specific recognition of the viral protein UL18 by CD85j/LIR-1/ILT2 on CD8C T cells mediates the non-MHC-restricted lysis of human cytomegalovirus-infected cells. J Immunol 2004; 172:5629-37; http://dx.doi.org/10.4049/jimmunol.172.9.5629
110. Wagner CS, Riise GC, Bergstrom T, Karre K, Carbone E, Berg L. Increased expression of leukocyte Ig-like receptor-1 and activating role of UL18 in the response to cytomegalovirus infection. J Immunol 2007; 178:3536-43; http://dx.doi.org/10.4049/jimmunol.178.6.3536
111. Merlo A, Tenca C, Fais F, Battini L, Ciccone E, Grossi CE, Saverino D. Inhibitory receptors CD85j, LAIR-1, and CD152 down-regulate immunoglobulin and cytokine production by human B lymphocytes. Clin Diagn Laborat Immunol 2005; 12:705-12
112. Naji A, Menier C, Morandi F, Agaugue S, Maki G, Ferretti E, Bruel S, Pistoia V, Carosella ED, Rouas-Freiss N. Binding of HLA-G to ITIM-bearing Ig-like transcript 2 receptor suppresses B cell responses. J Immunol 2014; 192:1536-46; http://dx.doi.org/10.4049/jimmunol.1300438
113. Kalmbach Y, Boldt AB, Fendel R, Mordmuller B, Kremsner PG, Kun JF. Increase in annexin V-positive B cells expressing LILRB1/ILT2/CD85j in malaria. Eur Cytokine Net 2006; 17:175-80
114. Manavalan JS, Kim-Schulze S, Scotto L, Naiyer AJ, Vlad G, Colombo PC, Marboe C, Mancini D, Cortesini R, Suciu-Foca N. Alloantigen specific CD8CCD28-FOXP3C T suppressor cells induce ILT3C ILT4C tolerogenic endothelial cells, inhibiting alloreactivity. Inter Immunol 2004; 16:1055-68 http://dx.doi.org/10.1093/intimm/dxh107
115. Masuda A, Nakamura A, Maeda T, Sakamoto Y, Takai T. Cis binding between inhibitory receptors and MHC class I can regulate mast cell activation. J Exp Med 2007; 204:907-20 http://dx.doi.org/10.1084/jem.20060631
116. Manavalan JS, Rossi PC, Vlad G, Piazza F, Yarilina A, Cortesini R, Mancini D, Suciu-Foca N. High expression of ILT3 and ILT4 is a general feature of tolerogenic dendritic cells. Transpl Immunol 2003; 11:245-58 http://dx.doi.org/10.1016/S0966-3274(03)00058-3
117. Bashirova AA, Martin-Gayo E, Jones DC, Qi Y, Apps R, Gao X, Burke PS, Taylor CJ, Rogich J, Wolinsky S, et al. LILRB2 interaction with HLA class I correlates with control of HIV-1 infection. PLoS genetics 2014; 10:e1004196 http://dx.doi.org/10.1371/journal.pgen.1004196
118. Brown DP, Jones DC, Anderson KJ, Lapaque N, Buerki RA, Trowsdale J, Allen RL. The inhibitory receptor LILRB4 (ILT3) modulates antigen presenting cell phenotype and, along with LILRB2 (ILT4), is upregulated in response to Salmonella infection. BMC Immunol 2009; 10:56 http://dx.doi.org/10.1186/1471-2172-10-56
119. Sloane DE, Tedla N, Awoniyi M, Macglashan DW, Jr., Borges L, Austen KF, Arm JP. Leukocyte immunoglobulin-like receptors: novel innate receptors for human basophil activation and inhibition. Blood 2004; 104:2832-9 http://dx.doi.org/10.1182/blood-2004-01-0268
120. Arm JP, Nwankwo C, Austen KF. Molecular identification of a novel family of human Ig superfamily members that possess immunoreceptor tyrosine-based inhibition motifs and homology to the mouse gp49B1 inhibitory receptor. J Immunol 1997; 159:2342-9
121. Vlad G, Chang CC, Colovai AI, Berloco P, Cortesini R, Suciu-Foca N. Immunoglobulin-like transcript 3: A crucial regulator of dendritic cell function. Hum Immunol 2009; 70:340-4 http://dx.doi.org/10.1016/j.humimm.2009.03.004
122. Kim-Schulze S, Seki T, Vlad G, Scotto L, Fan J, Colombo PC, Liu J, Cortesini R, Suciu-Foca N. Regulation of ILT3 gene expression by processing of precursor transcripts in human endothelial cells. Am J Transplant 2006; 6:76-82 http://dx.doi.org/10.1111/j.1600-6143.2005.01162.x
123. Chang CC, Silvia EA, Ho EK, Vlad G, Suciu-Foca N, Vasilescu ER. Polymorphism and linkage disequilibrium of immunoglobulin-like transcript 3 g ene. Hum Immunol 2008; 69:284-90 http://dx.doi.org/10.1016/j.humimm.2008.02.004
124. Cheng H, Mohammed F, Nam G, Chen Y, Qi J, Garner LI, Allen RL, Yan J, Willcox BE, Gao GF. Crystal structure of leukocyte Ig-like receptor LILRB4 (ILT3/LIR-5/CD85k): a myeloid inhibitory receptor involved in immune tolerance. J Biol Chem 2011; 286:18013-25 http://dx.doi.org/10.1074/jbc.M111.221028
125. Waschbisch A, Sanderson N, Krumbholz M, Vlad G, Theil D, Schwab S, Maurer M, Derfuss T. Interferon beta and vitamin D synergize to induce immunoregulatory receptors on peripheral blood monocytes of multiple sclerosis patients. PloS one 2014; 9:e115488 http://dx.doi.org/10.1371/journal.pone.0115488
126. Lu HK, Rentero C, Raftery MJ, Borges L, Bryant K, Tedla N. Leukocyte Ig-like receptor B4 (LILRB4) is a potent inhibitor of FcgammaRI-mediated monocyte activation via dephosphorylation of multiple kinases. J Biol Chem 2009; 284:34839-48 http://dx.doi.org/10.1074/jbc.M109.035683
127. Kim-Schulze S, Scotto L, Vlad G, Piazza F, Lin H, Liu Z, Cortesini R, Suciu-Foca N. Recombinant Ig-like transcript 3-Fc modulates T cell responses via induction of Th anergy and differentiation of CD8C T suppressor cells. J Immunol 2006; 176:2790-8 http://dx.doi.org/10.4049/jimmunol.176.5.2790
128. Vlad G, D’Agati VD, Zhang QY, Liu Z, Ho EK, Mohanakumar T, Hardy MA, Cortesini R, Suciu-Foca N. Immunoglobulin-like transcript 3-Fc suppresses T-cell responses to allogeneic human islet transplants in hu-NOD/SCID mice. Diabetes 2008; 57:1878-86 http://dx.doi.org/10.2337/db08-0054
129. Vlad G, Stokes MB, Liu Z, Chang CC, Sondermeijer H, Vasilescu ER, Colovai AI, Berloco P, D’Agati VD, Ratner L, et al. Suppression of xenogeneic graft-versus-host disease by treatment with immunoglobulin-like transcript 3-Fc. Hum Immunol 2009; 70:663-9 http://dx.doi.org/10.1016/j.humimm.2009.06.001
130. Chang CC, Liu Z, Vlad G, Qin H, Qiao X, Mancini DM, Marboe CC, Cortesini R, Suciu-Foca N. Ig-like transcript 3 regulates expression of proinflammatory cytokines and migration of activated T cells. J Immunol 2009; 182:5208-16; http://dx.doi.org/10.4049/jimmunol.0804048
131. Chang CC, Vlad G, D’Agati VD, Liu Z, Zhang QY, Witkowski P, Torkamani AA, Stokes MB, Ho EK, Cortesini R, et al. BCL6 is required for differentiation of Ig-like transcript 3-Fc-induced CD8C T suppressor cells. J Immunol 2010; 185:5714-22; http://dx.doi.org/10.4049/jimmunol.1001732
132. Ulges A, Klein M, Reuter S, Gerlitzki B, Hoffmann M, Grebe N, Staudt V, Stergiou N, Bohn T, Bruhl TJ, et al. Protein kinase CK2 enables regulatory T cells to suppress excessive TH2 responses in vivo. Nat Immunol 2015; 16:267-75 http://dx.doi.org/10.1038/ni.3083
133. de Goeje PL, Bezemer K, Heuvers ME, Dingemans AC, Groen HJ, Smit EF, Hoogsteden HC, Hendriks RW, Aerts JG, Hegmans JP. Immunoglobulin-like transcript 3 is expressed by myeloid-derived suppressor cells and correlates with survival in patients with nonsmall cell lung cancer. Oncoimmunology 2015; 4:e1014242 http://dx.doi.org/10.1080/2162402X.2015.1014242
134. Khan MF, Bahr JM, Yellapa A, Bitterman P, Abramowicz JS, Edassery SL, Basu S, Rotmensch J, Barua A. Expression of Leukocyte Inhibitory Immunoglobulin-like Transcript 3 Receptors by Ovarian Tumors in Laying Hen Model of Spontaneous Ovarian Cancer. Trans Oncol 2012; 5:85-91 http://dx.doi.org/10.1593/tlo.11328
135. Dube MP, Zetler R, Barhdadi A, Brown AM, Mongrain I, Normand V, Laplante N, Asselin G, Zada YF, Provost S, et al. CKM and LILRB5 are associated with serum levels of creatine kinase. Circul Cardiov Gen 2014; 7:880-6 http://dx.doi.org/10.1161/CIRCGENETICS.113.000395
136. Maeda A, Kurosaki M, Ono M, Takai T, Kurosaki T. Requirement of SH2-containing protein tyrosine phosphatases SHP-1 and SHP-2 for paired immunoglobulin-like receptor B (PIR-B)-mediated inhibitory signal. J Exp Med 1998; 187:1355-60 http://dx.doi.org/10.1084/jem.187.8.1355
137. Zhao J, Luo Y, Wang X, Zhou H, Li Q, You Y, Zou P. Prevention of murine acute graft-versus-host disease by recipient-derived paired immunoglobulin-like receptor B lentivirus-transfected dendritic cells. Acta Haematol 2010; 124:134-40 http://dx.doi.org/10.1159/000315553
138. Ujike A, Takeda K, Nakamura A, Ebihara S, Akiyama K, Takai T. Impaired dendritic cell maturation and increased T(H)2 responses in PIR-B(-/-) mice. Nat Immunol 2002; 3:542-8 http://dx.doi.org/10.1038/ni801
139. Munitz A, Cole ET, Beichler A, Groschwitz K, Ahrens R, Steinbrecher K, Willson T, Han X, Denson L, Rothenberg ME, et al. Paired immunoglobulin-like receptor B (PIR-B) negatively regulates macrophage activation in experimental colitis. Gastroenterol 2010; 139:530-41 http://dx.doi.org/10.1053/j.gastro.2010.04.006
140. Karo-Atar D, Moshkovits I, Eickelberg O, Konigshoff M, Munitz A. Paired immunoglobulin-like receptor-B inhibits pulmonary fibrosis by suppressing profibrogenic properties of alveolar macrophages. Am J Resp Cell Mol Biol 2013; 48:456-64 http://dx.doi.org/10.1165/rcmb.2012-0329OC
141. Imada M, Masuda K, Satoh R, Ito Y, Goto Y, Matsuoka T, Endo S, Nakamura A, Kawamoto H, Takai T. Ectopically expressed PIR-B on T cells constitutively binds to MHC class I and attenuates T helper type 1 responses. Int Immunol 2009; 21:1151-61 http://dx.doi.org/10.1093/intimm/dxp081
142. Munitz A, McBride ML, Bernstein JS, Rothenberg ME. A dual activation and inhibition role for the paired immunoglobulin-like receptor B in eosinophils. Blood 2008; 111:5694-703 http://dx.doi.org/10.1182/blood-2007-12-126748
143. Bochner DN, Sapp RW, Adelson JD, Zhang S, Lee H, Djurisic M, Syken J, Dan Y, Shatz CJ. Blocking PirB up-regulates spines and functional synapses to unlock visual cortical plasticity and facilitate recovery from amblyopia. Sci Trans Med 2014; 6:258ra140; http://dx.doi.org/10.1126/scitranslmed.3010157
144. Djurisic M, Vidal GS, Mann M, Aharon A, Kim T, Ferrao Santos A, Zuo Y, Hubener M, Shatz CJ. PirB regulates a structural substrate for cortical plasticity. Proc Natl Acad Sci U S A 2013; 110:20771-6 http://dx.doi.org/10.1073/pnas.1321092110
145. Syken J, Grandpre T, Kanold PO, Shatz CJ. PirB restricts oculardominance plasticity in visual cortex. Science 2006; 313:1795-800 http://dx.doi.org/10.1126/science.1128232
146. Kubagawa H, Chen CC, Ho LH, Shimada TS, Gartland L, Mashburn C, Uehara T, Ravetch JV, Cooper MD. Biochemical nature and cellular distribution of the paired immunoglobulin-like receptors, PIR-A and PIR-B. J Exp Med 1999; 189:309-18 http://dx.doi.org/10.1084/jem.189.2.309
147. Katz HR, LeBlanc PA, Russell SW. Two classes of mouse mast cells delineated by monoclonal antibodies. Proc Natl Acad Sci U S A 1983; 80:5916-8 http://dx.doi.org/10.1073/pnas.80.19.5916
148. LeBlanc PA, Biron CA. Mononuclear phagocyte maturation: a cytotoxic monoclonal antibody reactive with postmonoblast stages. Cell Immunol 1984; 83:242-54 http://dx.doi.org/10.1016/0008-8749(84)90303-4
149. Zhou JS, Friend DS, Feldweg AM, Daheshia M, Li L, Austen KF, Katz HR. Prevention of lipopolysaccharide-induced microangiopathy by gp49B1: evidence for an important role for gp49B1 expression on neutrophils. J Exp Med 2003; 198:1243-51 http://dx.doi.org/10.1084/jem.20030906
150. Wang LL, Chu DT, Dokun AO, Yokoyama WM. Inducible expression of the gp49B inhibitory receptor on NK cells. J Immunol 2000; 164:5215-20; http://dx.doi.org/10.4049/jimmunol.164.10.5215
151. Gu X, Laouar A, Wan J, Daheshia M, Lieberman J, Yokoyama WM, Katz HR, Manjunath N. The gp49B1 inhibitory receptor regulates the IFN-gamma responses of T cells and NK cells. J Immunol 2003; 170:4095-101; http://dx.doi.org/10.4049/jimmunol.170.8.4095
152. Kuroiwa A, Yamashita Y, Inui M, Yuasa T, Ono M, Nagabukuro A, Matsuda Y, Takai T. Association of tyrosine phosphatases SHP-1 and SHP-2, inositol 5-phosphatase SHIP with gp49B1, and chromosomal assignment of the gene. J Biol Chem 1998; 273:1070-4 http://dx.doi.org/10.1074/jbc.273.2.1070
153. Wang LL, Blasioli J, Plas DR, Thomas ML, Yokoyama WM. Specificity of the SH2 domains of SHP-1 in the interaction with the immunoreceptor tyrosine-based inhibitory motif-bearing receptor gp49B. J Immunol 1999; 162:1318-23
154. Lu-Kuo JM, Joyal DM, Austen KF, Katz HR. gp49B1 inhibits IgE-initiated mast cell activation through both immunoreceptor tyrosinebased inhibitory motifs, recruitment of src homology 2 domain-containing phosphatase-1, and suppression of early and late calcium mobilization. J Biol Chem 1999; 274:5791-6 http://dx.doi.org/10.1074/jbc.274.9.5791
155. Fukao S, Haniuda K, Nojima T, Takai T, Kitamura D. gp49B-mediated negative regulation of antibody production by memory and marginal zone B cells. J Immunol 2014; 193:635-44; http://dx.doi.org/10.4049/jimmunol.1302772
156. Daheshia M, Friend DS, Grusby MJ, Austen KF, Katz HR. Increased severity of local and systemic anaphylactic reactions in gp49B1-deficient mice. J Exp Med 2001; 194:227-34 http://dx.doi.org/10.1084/jem.194.2.227
157. Feldweg AM, Friend DS, Zhou JS, Kanaoka Y, Daheshia M, Li L, Austen KF, Katz HR. gp49B1 suppresses stem cell factor-induced mast cell activation-secretion and attendant inflammation in vivo. Eur J Immunol 2003; 33:2262-8 http://dx.doi.org/10.1002/eji.200323978
158. Zhou JS, Friend DS, Lee DM, Li L, Austen KF, Katz HR. gp49B1 deficiency is associated with increases in cytokine and chemokine production and severity of proliferative synovitis induced by anti-type II collagen mAb. Eur J Immunol 2005; 35:1530-8 http://dx.doi.org/10.1002/eji.200425895
159. Breslow RG, Rao JJ, Xing W, Hong DI, Barrett NA, Katz HR. Inhibition of Th2 adaptive immune responses and pulmonary inflammation by leukocyte Ig-like receptor B4 on dendritic cells. J Immunol 2010; 184:1003-13; http://dx.doi.org/10.4049/jimmunol.0900877
160. Fanning LB, Buckley CC, Xing W, Breslow RG, Katz HR. Downregulation of key early events in the mobilization of antigen-bearing dendritic cells by leukocyte immunoglobulin-like Receptor B4 in a mouse model of allergic pulmonary inflammation. PloS One 2013; 8: e57007
161. Minoo P, Zadeh MM, Rottapel R, Lebrun JJ, Ali S. A novel SHP-1/Grb2-dependent mechanism of negative regulation of cytokinereceptor signaling: contribution of SHP-1 C-terminal tyrosines in cytokine signaling. Blood 2004; 103:1398-407 http://dx.doi.org/10.1182/blood-2003-07-2617
162. Dance M, Montagner A, Salles JP, Yart A, Raynal P. The molecular functions of Shp2 in the Ras/Mitogen-activated protein kinase (ERK1/2) pathway. Cell Signal 2008; 20:453-9 http://dx.doi.org/10.1016/j.cellsig.2007.10.002
163. Meyaard L. LAIR and collagens in immune regulation. Immunol Lett 2010; 128:26-8 http://dx.doi.org/10.1016/j.imlet.2009.09.014
164. Perbellini O, Falisi E, Giaretta I, Boscaro E, Novella E, Facco M, Fortuna S, Finotto S, Amati E, Maniscalco F, et al. Clinical significance of LAIR1 (CD305) as assessed by flow cytometry in a prospective series of patients with chronic lymphocytic leukemia. Haematologica 2014; 99:881-7 http://dx.doi.org/10.3324/haematol.2013.096362
165. Poggi A, Catellani S, Bruzzone A, Caligaris-Cappio F, Gobbi M, Zocchi MR. Lack of the leukocyte-associated Ig-like receptor-1 expression in high-risk chronic lymphocytic leukaemia results in the absence of a negative signal regulating kinase activation and cell division. Leukemia 2008; 22:980-8 http://dx.doi.org/10.1038/leu.2008.21
166. Poggi A, Pellegatta F, Leone BE, Moretta L, Zocchi MR. Engagement of the leukocyte-associated Ig-like receptor-1 induces programmed cell death and prevents NF-kappaB nuclear translocation in human myeloid leukemias. Eur J Immunol 2000; 30:2751-8 http://dx.doi.org/10.1002/1521-4141(200010) 30:10%3c2751::AID-IMMU2751%3e3.0.CO;2-L
167. Zocchi MR, Pellegatta F, Pierri I, Gobbi M, Poggi A. Leukocyteassociated Ig-like receptor-1 prevents granulocyte-monocyte colony stimulating factor-dependent proliferation and Akt1/PKB alpha activation in primary acute myeloid leukemia cells. Eur J Immunol 2001; 31:3667-75 http://dx.doi.org/10.1002/1521-4141(200112)31:12%3c3667::AIDIMMU3667% 3e3.0.CO;2-G
168. Krivtsov AV, Twomey D, Feng Z, Stubbs MC, Wang Y, Faber J, Levine JE, Wang J, Hahn WC, Gilliland DG, et al. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature 2006; 442:818-22 http://dx.doi.org/10.1038/nature04980
169. Somervaille TC, Cleary ML. Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia. Cancer Cell 2006; 10:257-68 http://dx.doi.org/10.1016/j.ccr.2006.08.020
170. Yan M, Kanbe E, Peterson LF, Boyapati A, Miao Y, Wang Y, Chen IM, Chen Z, Rowley JD, Willman CL, et al. A previously unidentified alternatively spliced isoform of t(8;21) transcript promotes leukemogenesis. Nat Med 2006; 12:945-9 http://dx.doi.org/10.1038/nm1443
171. Sugihara E, Shimizu T, Kojima K, Onishi N, Kai K, Ishizawa J, Nagata K, Hashimoto N, Honda H, Kanno M, et al. Ink4a and Arf are crucial factors in the determination of the cell of origin and the therapeutic sensitivity of Myc-induced mouse lymphoid tumor. Oncogene 2011
172. Turner L, Lavstsen T, Berger SS, Wang CW, Petersen JE, Avril M, Brazier AJ, Freeth J, Jespersen JS, Nielsen MA, et al. Severe malaria is associated with parasite binding to endothelial protein C receptor. Nature 2013; 498:502-5 http://dx.doi.org/10.1038/nature12216
173. Frei AP, Jeon OY, Kilcher S, Moest H, Henning LM, Jost C, Pluckthun A, Mercer J, Aebersold R, Carreira EM, et al. Direct identification of ligand-receptor interactions on living cells and tissues. Nat Biotech 2012; 30:997-1001 http://dx.doi.org/10.1038/nbt.2354
174. Xu M, Zhao R, Zhao ZJ. Identification and characterization of leukocyteassociated Ig-like receptor-1 as a major anchor protein of tyrosine phosphatase SHP-1 in hematopoietic cells. J Biol Chem 2000; 275:17440-6 http://dx.doi.org/10.1074/jbc.M001313200
175. Eklund EA, Goldenberg I, Lu Y, Andrejic J, Kakar R. SHP1 proteintyrosine phosphatase regulates HoxA10 DNA binding and transcriptional repression activity in undifferentiated myeloid cells. J Biol Chem 2002; 277:36878-88 http://dx.doi.org/10.1074/jbc.M203917200
176. Verbrugge A, de Ruiter T, Geest C, Coffer PJ, Meyaard L. Differential expression of leukocyte-associated Ig-like receptor-1 during neutrophil differentiation and activation. J Leukoc Biol 2006; 79:828-36 http://dx.doi.org/10.1189/jlb.0705370
177. Nihal M Heiba SAE. SHP-1 expression in chronic myeloid leukemia (clinical significance and impact on response to imatinib treatment). Egypt J Haematol 2013; 38:84-9
178. Tibaldi E, Brunati AM, Zonta F, Frezzato F, Gattazzo C, Zambello R, Gringeri E, Semenzato G, Pagano MA, Trentin L. Lyn-mediated SHP-1 recruitment to CD5 contributes to resistance to apoptosis of B-cell chronic lymphocytic leukemia cells. Leukemia 2011; 25:1768-81 http://dx.doi.org/10.1038/leu.2011.152
179. Tapley P, Shevde NK, Schweitzer PA, Gallina M, Christianson SW, Lin IL, Stein RB, Shultz LD, Rosen J, Lamb P. Increased G-CSF responsiveness of bone marrow cells from hematopoietic cell phosphatase deficient viable motheaten mice. Exp Hematol 1997; 25:122-31
180. Jiao H, Yang W, Berrada K, Tabrizi M, Shultz L, Yi T. Macrophages from motheaten and viable motheaten mutant mice show increased proliferative responses to GM-CSF: detection of potential HCP substrates in GM-CSF signal transduction. Exp Hematol 1997; 25:592-600
181. Wu C, Guan Q, Wang Y, Zhao ZJ, Zhou GW. SHP-1 suppresses cancer cell growth by promoting degradation of JAK kinases. J Cell Biochem 2003; 90:1026-37 http://dx.doi.org/10.1002/jcb.10727
182. Lorenz U, Bergemann AD, Steinberg HN, Flanagan JG, Li X, Galli SJ, Neel BG. Genetic analysis reveals cell type-specific regulation of receptor tyrosine kinase c-Kit by the protein tyrosine phosphatase SHP1. J Exp Med 1996; 184:1111-26 http://dx.doi.org/10.1084/jem.184.3.1111
183. Paulson RF, Vesely S, Siminovitch KA, Bernstein A. Signalling by the W/Kit receptor tyrosine kinase is negatively regulated in vivo by the protein tyrosine phosphatase Shp1. Nat Genet 1996; 13:309-15 http://dx.doi.org/10.1038/ng0796-309
184. Koyama M, Oka T, Ouchida M, Nakatani Y, Nishiuchi R, Yoshino T, Hayashi K, Akagi T, Seino Y. Activated proliferation of B-cell lymphomas/leukemias with the SHP1 gene silencing by aberrant CpG methylation. Lab Invest 2003; 83:1849-58 http://dx.doi.org/10.1097/01.LAB.0000106503.65258.2B
185. Uhm KO, Lee ES, Lee YM, Park JS, Kim SJ, Kim BS, Kim HS, Park SH. Differential methylation pattern of ID4, SFRP1, and SHP1 between acute myeloid leukemia and chronic myeloid leukemia. J Korean Med Sci 2009; 24:493-7 http://dx.doi.org/10.3346/jkms.2009.24.3.493
186. Gauffin F, Diffner E, Gustafsson B, Nordgren A, Wingren AG, Sander B, Persson JL, Gustafsson B. Expression of PTEN and SHP1, investigated from tissue microarrays in pediatric acute lymphoblastic, leukemia. Pediat Hematol Oncol 2009; 26:48-56 http://dx.doi.org/10.1080/08880010802625530
187. Bard-Chapeau EA, Li S, Ding J, Zhang SS, Zhu HH, Princen F, Fang DD, Han T, Bailly-Maitre B, Poli V, et al. Ptpn11/Shp2 acts as a tumor suppressor in hepatocellular carcinogenesis. Cancer Cell 2011; 19: 629-39 http://dx.doi.org/10.1016/j.ccr.2011.03.023
188. Leal M, Sapra P, Hurvitz SA, Senter P, Wahl A, Schutten M, Shah DK, Haddish-Berhane N, Kabbarah O. Antibody-drug conjugates: an emerging modality for the treatment of cancer. Annal New York Acad Sci 2014; 1321:41-54 http://dx.doi.org/10.1111/nyas.12499
189. Gill S, June CH. Going viral: chimeric antigen receptor Tcell therapy for hematological malignancies. Immunol Rev 2015; 263:68-89 http://dx.doi.org/10.1111/imr.12243